MedTrace Logo

Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer

NCT01206426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2018-05-04

No results posted yet for this study

Summary

This is observational clinical trial to study adult urothelial cancer patients treated with cisplatin-based neoadjuvant chemotherapy.

Hypothesis: Identification of genetic and molecular "cisplatin susceptibility" biomarkers will allow identification of urothelial cancer patients most likely to benefit from cisplatin-based neoadjuvant chemotherapy.

Conditions

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Peter H O'Donnell, MD · University of Chicago

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2016-07-31
Completion
2017-10-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206426 on ClinicalTrials.gov